GlaxoSmithKline PLC (GSK) had an volatile session and gained 0.04 points till last call. The price was at $39.35, gaining 0.09% till the last intraday data. The total uptick value was $6.12 million while the total downtick value was $7.87 million. The shares saw a net money flow of $(-1.75) million and the up/down ratio stood at 0.78. The stock has seen a change of of 1.59% for the week. The share had a block transaction during the course of trading in which the net money flow was $(-2.18) million. Almost $0 million were received in upticks and approximately $2.18 million were lost in downticks, thereby giving the up/down ratio of 0.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of GlaxoSmithKline plc rose by 1.49% in the last five trading days and 2.47% for the last 4 weeks. GlaxoSmithKline plc has dropped 0.21% during the last 3-month period . Year-to-Date the stock performance stands at 2.47%. GlaxoSmithKline PLC (NYSE:GSK) rose 0.38% or 0.15 points on Wednesday and made its way into the gainers of the day. After trading began at $39.59 the stock was seen hitting $39.59 as a peak level and $39.15 as the lowest level. The stock ended up at $39.46. The daily volume was measured at 3,575,325 shares. The 52-week high of the share price is $45.58 and the 52-week low is $37.2. The company has a market cap of $96,132 million.
GlaxoSmithKline plc (ADR) Last issued its quarterly earnings results on Feb 3, 2016. The company reported $0.18 EPS for the quarter. Analyst had a consensus estimate of $0.18. The company had revenue of $6286.00 million for the quarter, compared to analysts expectations of $6276.33 million. During the same quarter in the previous year, the company posted $0.27 EPS.
GlaxoSmithKline is one of the worlds leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.